Lilly, Boehringer Ingelheim Get FDA Fast-Track Designation for Jardiance After Heart Attack
September 15 2020 - 8:47AM
Dow Jones News
By Colin Kellaher
Eli Lilly & Co. and Boehringer Ingelheim Tuesday said the
U.S. Food and Drug Administration granted fast-track designation
for the development of their diabetes drug Jardiance to improve
outcomes following a heart attack.
The companies in May announced plans plan to study whether
Jardiance can help prevent hospitalization for heart failure and
reduce the risk of mortality in patients with and without diabetes
who have had an acute myocardial infarction, more commonly known as
a heart attack.
The FDA's fast-track program is designed to facilitate the
development and expedite the review of drugs to treat serious
conditions and fill an unmet medical need.
Indianapolis-based drug maker Eli Lilly and Boehringer
Ingelheim, a family-owned pharmaceutical company based in
Ingelheim, Germany, jointly market Jardiance as part of a 2011
alliance.
The companies are currently exploring the impact of Jardiance on
patients across the spectrum of cardio-renal-metabolic
conditions.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 15, 2020 08:32 ET (12:32 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2023 to Apr 2024
